Novo Nordisk
Europe, Hovedstaden, Denmark, Bagsværd
Description
Novo Nordisk is a healthcare company that produces and distributes insulin and other diabetes drugs to treat chronic diseases.
Investor Profile
Novo Nordisk has backed more than 18 startups, with 3 new investments in the last 12 months alone. The firm has led 6 rounds, about 33% of its total and boasts 4 exits across its portfolio.
Investment Focus Highlights
- Concentrates on Series A, Series C, Series D rounds (top funding stages).
- Majority of deals are located in United States, Denmark, Canada.
- Strong thematic focus on Biotechnology, Health Care, Pharmaceutical.
- Led 2 rounds in the past year.
Stage Focus
- Series A (22%)
- Series C (17%)
- Series D (11%)
- Seed (11%)
- Corporate Round (11%)
- Pre Seed (6%)
- Series Unknown (6%)
- Series E (6%)
- Convertible Note (6%)
- Series B (6%)
Country Focus
- United States (56%)
- Denmark (11%)
- Canada (11%)
- The Netherlands (6%)
- France (6%)
- Germany (6%)
- Belgium (6%)
Industry Focus
- Biotechnology
- Health Care
- Pharmaceutical
- Therapeutics
- Life Science
- Diabetes
- Medical Device
- Medical
- Information Technology
- Clinical Trials
FAQ
Frequently Asked Questions
Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.
Who does Novo Nordisk frequently co-invest with?
What are some of recent deals done by Novo Nordisk?
Find More Investors Like Novo Nordisk
Discover similar investors in our database and build your perfect investor list.
Need help with your fundraising strategy?Read our fundraising guides
